Role of fludarabine as monotherapy in the treatment of chronic lymphocytic leukemia

Hematology Journal

Volumn 5, Issue SUPPL. 1, 2004, Pages

  Leporrier, Michel ^a  

^a CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

Chronic lymphocytic leukemia; Fludarabine; Purine analogs

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; FLUDARABINE; NUCLEOSIDE ANALOG; PREDNISONE; VIDARABINE; VINCRISTINE;

ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL STUDY; CLINICAL TRIAL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; FEVER; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HIGH RISK PATIENT; HUMAN; IMMUNE DEFICIENCY; INCIDENCE; LEUKEMIA REMISSION; MONOTHERAPY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PURE RED CELL ANEMIA; RESPIRATORY TRACT INFECTION; SURVIVAL TIME; THROMBOCYTOPENIA; VISUAL DISORDER; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; TREATMENT OUTCOME; VIDARABINE;

EID: 2942619087     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200387     Document Type: Article

References (68)

1. Grant S. Ara-C: cellular and molecular pharmacology. Adv Cancer Res 1998; 72: 197-233.
2. Cohen SS. The mechanism of lethal action of arabinosyl cytosine (ara-C) and arabinosyl adenine (ara-A). Cancer 1977; 40 (Suppl 1): 509-518.
3. Montgomery JA, Hewson K. Nucleosides of 2-fluoroadenine. J Med Chem 1969; 12: 498-504.
4. Barrueco JR, Jacobsen DM, Chang CH, Brockman RW, Sirotnak FM. Proposed mechanism of therapeutic selectivity of 9-β-D-arabinofuranosyl-2-fluoroadenine against murine leukemia based upon lower capacities for transport and phosphorylation in proliferative intestinal epithelium compared to tumor cells. Cancer Res 1987; 47: 700-706.
5. Ross SR, McTavish D, Faulds D. Fludarabine: a review of its pharmacological properties and therapeutic potential in malignancy. Drugs 1993; 45: 737-759.
6. Plunkett W, Gandhi V, Huang P, Robertson LE, Yang LY, Gregoire V et al. Fludarabine: pharmacokinetics, mechanism of action, and rationales for combination therapy. Semin Oncol 1993; 20 (Suppl 7): 2-12.
7. Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet 2002; 41: 93-103.
8. Huang P, Chubb S, Plunkett W. Termination of DNA synthesis by 9-β-D-arabinofuranosyl-2-fluoroadenine: a mechanism for cytotoxicity. J Biol Chem 1990; 265: 16617-16625.
9. Huang P, Sandova A, Van den Neste E, Keating MJ, Plunkett W. Inhibition of RNA transcription: a biochemical mechanism of fludarabine-induced apoptosis in chronic lymphocytic leukaemia cells. Leukemia 2000; 14: 1405-1413.
10. Malspeis L, Grever MR, Staubus AE, Young D. Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate. Semin Oncol 1990; 17 (Suppl 8): 18-32.
11. Adkins JC, Peters DH, Markham A. Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies. Drugs 1997; 53: 1005-1037.
12. Gandhi V, Kemena A, Keating MJ. Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukaemia cells during fludarabine therapy. Leuk Lymphoma 1993; 10: 49-56.
13. Cheson BD, Bennett JM, Rai KR, Grever MR, Kay NE, Schiffer CA et al. Guidelines for clinical protocols for chronic lymphocytic leukaemia: recommendations of the National Cancer Institute-sponsored working group. Am J Hematol 1988; 29: 152-163.
14. Keating MJ, Kantarjian H, O'Brien S, Koller C, Talpaz M, Schachner J et al. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol 1991; 9: 44-49.
15. Keating MJ, O'Brien S, Kantarjian H, Plunkett W, Estey E, Koller C et al. Long-term follow-up of patients with chronic lymphocytic leukaemia treated with fludarabine as a single agent. Blood 1993; 81: 2878-2884.
16. Clavio M, Miglino M, Spriano M, Pietrasanta D, Vallebella E, Celesti L et al. First-line fludarabine treatment of symptomatic chronic lymphoproliferative diseases: clinical results and molecular analysis of minimal residual disease. Eur J Haematol 1998; 61: 197-203.
17. Stelitano C, Morabito F, Kropp MG, Callea V, Iuliano F, Oriana F et al. Fludarabine treatment in B-cell chronic lymphocytic leukaemia: response, toxicity and survival analysis in 47 cases. Haematologica 1999; 84: 317-323.
18. French Cooperative Group on CLL. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. Lancet 1996; 347: 1432-1438.
19. Leporrier M, Chevret S, Cazin B, Boudjerra N, Feugier P, Desablens B et al. Randomized comparison of fludarabine, CAP and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukaemia patients. Blood 2001; 98: 2319-2325.
20. Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukaemia. N Engl J Med 2000; 343: 1750-1757.
21. Spriano M, Chiurazzi F, Cassibba V, Leoni P, Liso V, Mazza P et al. Multicentric prospective randomised trial of fludarabine versus chlorambucil and prednisone in previously untreated patients with active B-chronic lymphocytic leukaemia (B-CLL): first interim report. Br J Haematol 1998; 102: 191 (abstract P-0761).
22. Schmitt BF, Posse K, Busch R, Kuhn-Hallek I, Emmerich B, Hallek M. Evaluation of fludarabine therapy in the different trials of the German chronic lymphocytic leukemia (CLL) study group (GCLLSG) reveals fewer side effects in early stage and older patients (Abstract 5016). American Society of Hypertension: Philadelphia, PA, 6-10 December 2002.
23. Spriano M, Chiurazzi F, Liso V, Mazza P, Molica S, Gobbi M. Multicentre prospective randomized trial of fludarabine versus chlorambucil and prednisone in previously untreated patients with active B-CLL (Abstract P-086). IWCLL - VIII International Workshop on Chronic Lymphocytic Leukemia. Paris, 29-31 October 1999.
24. Levy V, Porcher R, Delabarre F, Leporrier M, Cazin B, Chevret S, for the French Cooperative CLL Group. Evaluating treatment strategies in chronic lymphocytic leukaemia: use of quality-adjusted survival analysis. J Clin Epidemiol 2001; 54: 747-754.
25. Montserrat E, Poziopoulos F, Rozman C. B-cell chronic lymphocytic leukemia: recent progress in biology, diagnosis and therapy. Ann Oncol 1997; 8 (Suppl 1): S93-S101.
26. Angelopoulou MA, Poziopoulos C, Boussiotis VA, Kontopidou F, Pangalis GA. Fludarabine monophosphate in refractory B-chronic lymphocytic leukaemia. Maintenance may be significant to sustain response. Leuk Lymphoma 1996; 21: 321-324.
27. Fenchel K, Bergmann L, Wijermans P, Engert A, Pralle H, Mitrou PS et al. Clinical experience with fludarabine and its immunosuppressive effects in pretreated chronic lymphocytic leukaemias and low-grade lymphomas. Leuk Lymphoma 1995; 18: 485-492.
28. Gillis S, Dann EJ, Cass Y, Rochlemer R, Polliack A. Activity of fludarabine in refractory chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma, the Jerusalem experience. Leuk Lymphoma 1994; 15: 173-175.
29. Gjedde SB, Hansen MM. Salvage therapy with fludarabine in patients with progressive B-chronic lymphocytic leukaemia. Leuk Lymphoma 1996; 21: 317-320.
30. Grever MR, Kopecky KJ, Coltman CA, Files JC, Greenberg BR, Hutton JJ et al. Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. Nouv Rev Fr Hematol 1988; 30: 457-459.
31. Hensel M, Fischer K, Haas R, Witt B, Döhmer H, Hunstein W. Fludarabine phosphate in the treatment of advanced stage chronic lymphocytic leukaemia. Ann Hematol 1993; 67 (Suppl): A49 (abstract 190).
32. Hiddemann W, Rottmann R, Wörmann B, Thiel A, Essink M, Ottensmeier C et al. Treatment of advanced chronic lymphocytic leukemia by fludarabine: results of a clinical phase II study. Ann Hematol 1991; 63: 1-4.
33. Hocepied AM, Falkson CI, Falkson G. A phase II trial of fludarabine in patients with previously treated chronic lymphocytic leukemia. S Afr Med J 1996; 86: 549-550.
34. Johnson SA, Hiddeman W, Coiffier B, Fenaux P, Smith A, Loffler H et al. Fludarabine in the treatment of chronic lymphocytic leukaemia. Ann Oncol 1994; 5 (Suppl 5): 141 (abstract 277).
35. Keating MJ, Kantarjian H, Talpaz M, Redman J, Koller C, Barlogie B et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukaemia. Blood 1989; 74: 19-25.
36. Knauf WU, Kreuser ED, Pottgiesser E, Thiel E. In vitro and in vivo effectiveness of fludarabine in B-cell chronic lymphocytic leukaemia (B-CLL). Ann Hematol 1992; 65 (Suppl): A80 (abstract 203).
37. Montserrat E, Lopez-Lorenzo JL, Manso F, Martin A, Prieto E, Arias-Sampedro J et al. Fludarabine in resistant or relapsing B-cell chronic lymphocytic leukemia. The Spanish experience. Leuk Lymphoma 1996; 21: 467-472.
38. Montillo M, Tedeschi A, Delfini C, Olivieri A, D'Adamo F, Leoni P. Effectiveness of fludarabine in advanced B-cell chronic lymphocytic leukaemia. Tumori 1995; 81: 419-423.
39. O'Brien ME, Matutes E, Cunningham D, Hill M, Emmett E, Ellis PA et al. Fludarabine in lymphoproliferative disorders: the Royal Marsden Hospital experience. Leuk Lymphoma 1994; 14 (Suppl 2): 17-23.
40. Puccio CA, Mittelman A, Lichtman SM, Silver RT, Budman DR, Ahmed T et al. A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukaemia. J Clin Oncol 1991; 9: 1562-1569.
41. Robertson LE, O'Brien S, Kantarjian H, Koller C, Beran M, Andreeff M et al. A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukaemia. Leukemia 1995; 9: 1444-1449.
42. Sorensen JM, Vena DA, Fallavollita A, Chun HG, Cheson BD. Treatment of refractory chronic lymphocytic leukaemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: 5-year follow-up report. J Clin Oncol 1997; 15: 458-465.
43. Wijermans PW, Gerrits WB, Haak HL. Severe immunodeficiency in patients treated with fludarabine monophosphate. Eur J Haematol 1993; 50: 292-296.
44. Zinzani PL, Lauria F, Rondelli D, Benfanati D, Raspadori D, Bocchia M et al. Fludarabine in patients with advanced and/or resistant B-chronic lymphocytic leukaemia. Eur J Haematol 1993; 51: 93-97.
45. Schering AG, data on file.
46. Bezares RF, Murro HH, Celebrin L, Caviglia D, Lafalce D, Alcorta S. Fludarabine administered on a three (F3a) alternate day-basis in selected CLL patients. IX International Workshop on CLL San Diego, CA, 14-16 September 2001.
47. Thomas DA, O'Brien SM, Kantarjian HM, Giles FJ, Cortes J, Keating MJ. Retreatment with fludarabine: outcome in 203 patients with relapsed or refractory CLL treated with salvage therapy (abstract P084). IWCLL VIII International Workshop on CLL. Paris, 29-31 October 1999.
48. Cheson BD, Vena DA, Barrett J, Freidlin B. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukaemias. J Clin Oncol 1999; 17: 2454-2460.
49. O'Brien S, Kantarjian H, Beran M, Smith T, Koller C, Estey E et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukaemia with multivariate analysis-derived prognostic model for response to treatment. Blood 1993; 82: 1695-1700.
50. Busuttil DP, Chasty RC, Copplestone JA, Hamon MD, Prentice AG et al. Infections complicating treatment of lymphoid malignancies with fludarabine. Br J Haematol 1996; 93 (Suppl 1): 69.
51. Flinn IW, Grever MR. Chronic lymphocytic leukaemia. Cancer Treatment Rev 1996; 22: 1-13.
52. Cheson BD, Vena DA, Foss FM, Sorensen JM. Neurotoxicity of purine analogs: a review. J Clin Oncol 1994; 12: 2216-2228.
53. Myint H, Copplestone JA, Orchard J, Craig V, Curtis D, Prentice AG et al. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol 1995; 91: 341-344.
54. Maclean R, Meiklejohn D, Soutar R. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol 1996; 92: 768-769.
55. Weiss RB, Freiman J, Kweder SL, Diehl LF, Byrd JC. Hemolytic anemia after fludarabine for chronic lymphocytic leukaemia. J Clin Oncol 1998; 16: 1885-1889.
56. Leach M, Parsons RM, Reilly JT, Winfield DA. Autoimmune thrombocytopenia: a complication of fludarabine therapy in lymphoproliferative disorders. Clin Lab Haematol 2000; 22: 175-178.
57. Leporrier M, Reman O, Troussard X. Pure red cell aplasia with fludarabine for chronic lymphocytic leukaemia. Lancet 1993; 342: 555.
58. Schmitt BF, Kneba M, Ritgen M, Stauch M, Emmerich B, Bergmann M et al. First-line therapy of patients with advanced chronic lymphocytic leukemia older than 65 years with fludarabine versus chlorambucil: Interim analysis of a Phase III study of the German CLL study group (GCLLSG) (abstract 1501). American Society of Hypertension: Philadelphia PA, 6-10 December 2002.
59. Dreger P, Montserrat E. Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia. Leukemia 2002; 16: 985-992.
60. Rizouli V, Gribben JG. Role of autologous stem cell transplantation in chronic lymphocytic leukemia. Curr Opin Hematol 2003; 10: 306-311.
61. Sala R, Mauro FR, Bellucci R, De Propris MS, Cordone I, Lisci A et al. Evaluation of marrow and blood haemopoietic progenitors in chronic lymphocytic leukaemia before and after chemotherapy. Eur J Haematol 1998; 61: 14-20.
62. Tournilhac O, Cazin B, Lepretre S, Divine M, Maloum K, Delmer A et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukaemia. Blood 2004; 103: 363-365.
63. Ketterer N, Salles G, Moullet I, Dumontet C, El Jaafari-Corbin A, Tremisi P et al. Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol 1998; 103: 235-242.
64. Visani G, Lemoli RM, Tosi P, Martinelli G, Testoni N, Ricci P et al. Fludarabine-containing regimens severely impair peripheral blood stem cell mobilization and collection in acute myeloid leukaemia patients. Br J Haematol 1999; 105: 775-779.
65. Laszlo D, Galieni P, Raspadori D, Scalia G, Bigazzi C, Bocchia M et al. Fludarabine-containing regimens may adversely affect peripheral blood stem cell collection in low-grade non-Hodgkin's lymphoma patients. Leuk Lymphoma 2000; 37: 157-161.
66. Itälä M, Pelliniemi TT, Rajamaki A, Remes K. Autologous blood cell transplantation in B-CLL: response to chemotherapy prior to mobilization predicts the stem cell yield. Bone Marrow Transplant 1997; 19: 647-651.
67. Schey S, Ahsan G, Jones R. Dose intensification and molecular responses in patients with chronic lymphocytic leukaemia: a phase II single-centre study. Bone Marrow Transplant 1999; 24: 989-993.
68. Michallet M, Thiébaut A, Dreger P, Remes K, Milpied N, Santini G et al. Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukaemias Working Party (CLWP). Br J Haematol 2000; 108: 595-601.